Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Intensity Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Intensity Therapeutics, Inc.’s stock price such as:

• Intensity Therapeutics, Inc.’s current stock price and volume
• Why Intensity Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for INTS from analysts
• INTS’s stock price momentum as measured by its relative strength

About Intensity Therapeutics, Inc. (INTS)

Before we jump into Intensity Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Want to learn more about Intensity Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Intensity Therapeutics, Inc..

Intensity Therapeutics, Inc.’s Stock Price as of Market Close

As of November 24, 2025, 9:59 AM, CST, Intensity Therapeutics, Inc.’s stock price was $0.395.

Intensity Therapeutics, Inc. is down 3.26% from its previous closing price of $0.408.

During the last market session, Intensity Therapeutics, Inc.’s stock traded between $0.394 and $0.420. Currently, there are approximately 43.04 million shares outstanding for Intensity Therapeutics, Inc..

Intensity Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Intensity Therapeutics, Inc. Stock Price History

Intensity Therapeutics, Inc.’s (INTS) price is currently down 45.91% so far this month.

During the month of November, Intensity Therapeutics, Inc.’s stock price has reached a high of $0.710 and a low of $0.375.

Over the last year, Intensity Therapeutics, Inc. has hit prices as high as $3.176 and as low as $0.185. Year to date, Intensity Therapeutics, Inc.’s stock is down 77.56%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Intensity Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 21, 2025,, no analysts have changed their rating of Intensity Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Intensity Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Intensity Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Intensity Therapeutics, Inc. (INTS) by visiting AAII Stock Evaluator.

Relative Price Strength of Intensity Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 21, 2025, Intensity Therapeutics, Inc. has a weighted four-quarter relative price strength of -12.60%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Intensity Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Intensity Therapeutics, Inc. Stock Price: Bottom Line

As of November 24, 2025, Intensity Therapeutics, Inc.’s stock price is $0.395, which is down 3.26% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Intensity Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.